IL299326A - Clinical formulations - Google Patents

Clinical formulations

Info

Publication number
IL299326A
IL299326A IL299326A IL29932622A IL299326A IL 299326 A IL299326 A IL 299326A IL 299326 A IL299326 A IL 299326A IL 29932622 A IL29932622 A IL 29932622A IL 299326 A IL299326 A IL 299326A
Authority
IL
Israel
Prior art keywords
solution
preparation
optionally
cells
hours
Prior art date
Application number
IL299326A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of IL299326A publication Critical patent/IL299326A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • A01N1/12Chemical aspects of preservation
    • A01N1/122Preservation or perfusion media
    • A01N1/126Physiologically active agents, e.g. antioxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/39Pancreas; Islets of Langerhans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04Preserving or maintaining viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0621Eye cells, e.g. cornea, iris pigmented cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/60Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
IL299326A 2015-08-18 2016-08-18 Clinical formulations IL299326A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
PCT/US2016/047545 WO2017031312A1 (en) 2015-08-18 2016-08-18 Clinical formulations

Publications (1)

Publication Number Publication Date
IL299326A true IL299326A (en) 2023-02-01

Family

ID=56843032

Family Applications (3)

Application Number Title Priority Date Filing Date
IL299326A IL299326A (en) 2015-08-18 2016-08-18 Clinical formulations
IL257551A IL257551B (en) 2015-08-18 2018-02-15 Clinical formulations
IL291163A IL291163B2 (en) 2015-08-18 2022-03-07 Clinical formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL257551A IL257551B (en) 2015-08-18 2018-02-15 Clinical formulations
IL291163A IL291163B2 (en) 2015-08-18 2022-03-07 Clinical formulations

Country Status (15)

Country Link
US (4) US11013808B2 (enExample)
EP (1) EP3334415A1 (enExample)
JP (3) JP7043392B2 (enExample)
KR (3) KR20230058544A (enExample)
CN (2) CN108697641A (enExample)
AU (2) AU2016308818B2 (enExample)
BR (1) BR112018003031B1 (enExample)
EA (2) EA037915B1 (enExample)
HK (1) HK1256839A1 (enExample)
IL (3) IL299326A (enExample)
MX (2) MX2018002038A (enExample)
PH (1) PH12018500371B1 (enExample)
SG (1) SG10201913250SA (enExample)
TW (2) TWI833293B (enExample)
WO (1) WO2017031312A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
MX2017008737A (es) 2014-12-30 2018-01-25 Cell Cure Neurosciences Ltd Poblaciones de celulas rpe y metodos para generar las mismas.
CA2980580C (en) 2015-03-23 2024-01-23 Astellas Institute For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
WO2017031312A1 (en) 2015-08-18 2017-02-23 Astellas Institute For Regenerative Medicine Clinical formulations
JP7067744B2 (ja) * 2016-06-30 2022-05-16 株式会社ヘリオス 移植用媒体
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20240161220A (ko) * 2017-12-29 2024-11-12 셀 큐어 뉴로사이언시스 리미티드 망막 색소 상피 세포 조성물
KR20220054359A (ko) 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
IL292610A (en) 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for the production of retinal pigment epithelial cells
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
WO2023288115A1 (en) * 2021-07-15 2023-01-19 Sio2 Medical Products, Inc. Preservative composition for nucleic acids and biological samples and methods of use
JPWO2023176906A1 (enExample) * 2022-03-16 2023-09-21
CA3259999A1 (en) 2022-07-18 2024-01-25 Astellas Institute For Regenerative Medicine METHODS OF TREATING A BRAIN INJURY
JP2025530638A (ja) 2022-08-23 2025-09-17 アステラス インスティテュート フォー リジェネレイティブ メディシン 光受容体レスキュー細胞(prc)組成物および眼障害の処置のための方法
EP4659755A1 (en) * 2023-02-14 2025-12-10 RACTHERA Co., Ltd. Therapeutic drug for retinal pigment epithelium tears
WO2025122978A1 (en) * 2023-12-06 2025-06-12 Bluerock Therapeutics Lp Cell cryopreservation and delivery vehicle and methods of using the same
FR3158635A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible particulière comprenant des éléments cellulaires hétérogènes utile pour l’administration de thérapies cellulaires
WO2025158058A1 (fr) * 2024-01-26 2025-07-31 Treefrog Therapeutics Composition biocompatible comprenant des elements cellulaires heterogenes
FR3158633A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible comprenant des éléments cellulaires hétérogènes
WO2025204688A1 (ja) * 2024-03-26 2025-10-02 株式会社ダイセル リン脂質膜保護用液体組成物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
DE69227179D1 (de) * 1992-03-27 1998-11-05 Chen Chung Ho Mittel für Gewebe zur Erhaltung der Lebensfähigkeit und biologische Funktionen in der Chirurgie und Lagerung
RU2142282C1 (ru) 1993-06-04 1999-12-10 Биотайм, Инк Раствор кровезаменителя на водной основе и способ его получения
IT1277707B1 (it) 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
CN1152668C (zh) * 1997-08-22 2004-06-09 清水制药株式会社 含有葡萄糖的制剂
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
WO2001051065A1 (en) 2000-01-11 2001-07-19 Ophtecs Corporation Perfusion liquid preparations for ophthalmic operations
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2438814A3 (en) 2004-01-23 2012-10-03 Advanced Cell Technology, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
EP2377925A1 (en) 2006-04-14 2011-10-19 Advanced Cell Technology, Inc. Hemangio-colony forming cells
EP2617428A1 (en) 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
DK2209888T3 (da) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
CA3186451A1 (en) 2008-05-06 2009-11-12 Astellas Institute For Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
KR20120102709A (ko) 2009-11-17 2012-09-18 어드밴스드 셀 테크놀로지, 인코포레이티드 인간 rpe 세포의 생산 방법 및 인간 rpe 세포의 제약 제제
WO2011069127A1 (en) 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
US8822218B2 (en) 2009-12-04 2014-09-02 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
WO2012012803A2 (en) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
TW202434266A (zh) 2011-11-14 2024-09-01 安斯泰來再生醫藥協會 人類rpe細胞之醫藥組合物及其用途
TW202537630A (zh) 2011-11-30 2025-10-01 美商安斯泰來再生醫藥協會 利用血管母細胞產生間葉基質細胞之方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
PL2788472T3 (pl) 2011-12-06 2019-06-28 Astellas Institute For Regenerative Medicine Sposób ukierunkowanego różnicowania z wytwarzaniem komórek śródbłonka rogówki
CN103783031B (zh) * 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
AU2013201546B2 (en) 2012-12-18 2014-10-23 Gambro Lundia Ab Dialysis composition
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
EP4292600A3 (en) 2013-03-15 2024-04-10 Astellas Institute for Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP3189135B1 (en) 2014-09-05 2021-06-02 Astellas Institute for Regenerative Medicine Retinal ganglion cells and progenitors thereof
CA2980580C (en) 2015-03-23 2024-01-23 Astellas Institute For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
WO2017031312A1 (en) * 2015-08-18 2017-02-23 Astellas Institute For Regenerative Medicine Clinical formulations
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
KR20220054359A (ko) 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
IL292610A (en) 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for the production of retinal pigment epithelial cells
MX2023013079A (es) 2021-05-03 2023-11-16 Astellas Inst For Regenerative Medicine Metodos de generacion de celulas maduras del endotelio corneal.

Also Published As

Publication number Publication date
KR102411018B1 (ko) 2022-06-20
JP7449915B2 (ja) 2024-03-14
EA037915B1 (ru) 2021-06-07
US20240350639A1 (en) 2024-10-24
EP3334415A1 (en) 2018-06-20
JP2022040140A (ja) 2022-03-10
AU2022206757B2 (en) 2024-09-05
PH12018500371B1 (en) 2023-01-20
JP2018523682A (ja) 2018-08-23
NZ740608A (en) 2023-09-29
US11957754B2 (en) 2024-04-16
EA201890516A1 (ru) 2018-09-28
EA202190722A1 (ru) 2021-10-29
TWI833293B (zh) 2024-02-21
US20190030168A1 (en) 2019-01-31
MX2018002038A (es) 2018-07-06
US11013808B2 (en) 2021-05-25
BR112018003031B1 (pt) 2023-12-26
US12419958B2 (en) 2025-09-23
MX2022010363A (es) 2022-09-21
TW201717912A (zh) 2017-06-01
IL257551B (en) 2022-04-01
BR112018003031A2 (pt) 2018-09-18
CN108697641A (zh) 2018-10-23
IL291163A (en) 2022-05-01
IL291163B2 (en) 2023-05-01
KR20230058544A (ko) 2023-05-03
KR102651291B1 (ko) 2024-03-26
AU2022206757A1 (en) 2022-08-18
KR20180048722A (ko) 2018-05-10
WO2017031312A1 (en) 2017-02-23
HK1256839A1 (zh) 2019-10-04
AU2016308818B2 (en) 2022-04-21
JP7043392B2 (ja) 2022-03-29
US20210275673A1 (en) 2021-09-09
AU2016308818A1 (en) 2018-04-05
CA2995977A1 (en) 2017-02-23
KR20220090583A (ko) 2022-06-29
CN119112939A (zh) 2024-12-13
SG10201913250SA (en) 2020-03-30
TW202245816A (zh) 2022-12-01
JP2024074803A (ja) 2024-05-31
PH12018500371A1 (en) 2018-08-29
IL257551A (en) 2018-04-30
TW202417023A (zh) 2024-05-01
US20190358330A9 (en) 2019-11-28
TWI772270B (zh) 2022-08-01
IL291163B1 (en) 2023-01-01
US20260053930A1 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
IL299326A (en) Clinical formulations
JP2018523682A5 (enExample)
AU2014300400B2 (en) Trehalose and dextran-containing solution for transplanting mammalian cells
JP2025176149A (ja) アトロピン含有水性組成物
JP6879949B2 (ja) 治療目的のための細胞の凍結保存方法
WO2011021618A1 (ja) 細胞の保存方法
JP2013523823A (ja) 胎盤幹細胞を用いるサルコイドーシスの治療
US20190274300A1 (en) Preservative solution for live cells or composition containing live cells
JP2018521027A (ja) 周囲温度または亜正常温度での組織保存のための組成物および方法
US20190275088A1 (en) Preservative solution for live cells or composition containing live cells
US20240041023A1 (en) Composition and method of preserving viability of cell in a low temperature
JP2009219376A (ja) 医療用細胞の保護用液
TWI899072B (zh) 包含海藻醣之哺乳動物細胞保存用液
US20210244016A1 (en) Method for the Cryopreservation of Cells for Therapeutic Purposes
CN107105640A (zh) 具有控制的钙离子水平的新型组合物和溶液以及用于再灌注的相关方法和用途
RU2498570C1 (ru) Раствор для хранения роговицы
RU2450515C1 (ru) Средство для консервации донорской роговицы
RU2710167C1 (ru) Универсальное средство для гипотермической консервации трансплантата роговицы
WO2018003908A1 (ja) 移植用媒体
US20220041989A1 (en) Cellular culture medium free from serum
US20210368780A1 (en) Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof
US20260055378A1 (en) Powder formulations and use thereof in medical and/or surgical procedures
Wang et al. Advances in corneal preservation: a comparative narrative review of active and non-active methods
JP2000191401A (ja) 臓器保存剤
CA3220730A1 (en) Compositions and methods for lung preservation